BackArctic Bioscience AS Overview

Arctic Bioscience AS Long Term Debt

Latest long-term debt for ABS.OL: $43M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$43.42M
↑ 53.97% YoYΔ $15.22M vs prior year quarter

Peer trimmed avg / median

Loading

Arctic Bioscience AS Long Term Debt History

Loading

Arctic Bioscience AS vs. peers: Long Term Debt Comparison

Loading

Arctic Bioscience AS Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Arctic Bioscience AS (ABS.OL) FAQ

The latest long-term debt for ABS.OL is $43M as of June 2026. That compares with $28M in the prior-year period — up 54.0% year over year. Investors often review this figure alongside Arctic Bioscience AS's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABS.OL's long-term debt moved from $28M to $43M — a 54.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Arctic Bioscience AS's operating scale or balance-sheet position.

A long-term debt figure of $43M for ABS.OL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ABS.OL's long-term debt ($43M), review year-over-year change from $28M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Arctic Bioscience AS's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.

Questions & Answers